Navigation Links
Discovery Labs Appoints John R. Leone to Board of Directors
Date:11/14/2012

WARRINGTON, Pa., Nov. 14, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced it has appointed John R. Leone to the Company's Board of Directors, effective immediately.

"With over three decades of experience and an outstanding track record in pharmaceutical operations, commercial portfolio management, and financing life science companies, John's expertise will be invaluable to our Board," said W. Thomas Amick, Chairman of the Board and Chief Executive Offer at Discovery Labs, "As we prepare for the commercial launch of SURFAXIN® and continue the development of AEROSURF® and SURFAXIN LS™, John will bring an important perspective in guiding the business and financial strategies we employ as we build our Company."

Since 2007, Mr. Leone has been a Partner at Paul Capital Healthcare, a leading private equity firm that manages one of the largest dedicated healthcare funds globally.  At Paul Capital, Mr. Leone has focused on investment opportunities in commercial-stage life science companies.  From 2004 to 2006, Mr. Leone was President and Chief Executive Officer at Cambrex Corporation, a publicly-traded life sciences company providing innovative solutions that accelerate the development and commercialization of pharmaceutical products.  Previously, Mr. Leone served as Senior Vice President and Chief Operating Officer of U.S. Commercial Operations at Aventis Pharmaceuticals.  In this position he had responsibility for all commercial business units, including oncology, metabolism, cardiovascular, dermatology, respiratory and anti-infective.  Mr. Leone played a key role in spearheading the successful integration of its predecessor companies, Rhone-Poulenc Rorer and Hoechst Marion Roussel, to form Aventis.

"I am excited to join the Board to help guide and provide strategic input at this important juncture for the Company." said John R. Leone, "I am impressed with Discovery Labs' KL4 surfactant and aerosol delivery technologies and believe they have the potential to advance a new standard in respiratory critical care, beginning by addressing the unmet needs of premature infants at risk for respiratory distress syndrome (RDS).  I look forward to being a part of that change."

Mr. Leone's commercial experience also includes significant domestic and international executive management roles with Wyeth, where he held the following positions during his tenure: General Manager, Ayerst International; General Manager of commercial operations for Ayerst U.S.; Group Vice President of Wyeth International Marketing and General Manager, Vaccine and Pediatric Division.  Mr. Leone started his healthcare career at Pfizer Laboratories, where he held various senior marketing positions in both the U.S. and International groups and was responsible for the commercial launch of numerous pharmaceutical products.

Mr. Leone also serves on the Board of Directors at ViroPharma Incorporated.  Mr. Leone received his BS degree in Engineering from the U.S. Military Academy at West Point and his MBA from the University of Colorado.

ABOUT DISCOVERY LABS
Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to advance a new standard in respiratory critical care.  Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized, and aerosolized dosage forms. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies.  For more information, please visit our website at www.Discoverylabs.com.

Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.  Examples of such risks and uncertainties, including those related to the potential commercial introduction of SURFAXIN and AFECTAIR and Discovery Labs' research and development programs are described in Discovery Labs' filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.


'/>"/>
SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aptuit Drug Discovery & Development Center In Verona, Italy Hits 100th Client Milestone
2. Del Mar CEO Delivers Keynote Address at International Drug Discovery Science and Technology Conference
3. Discovery Labs Reports Third Quarter 2012 Financial Results
4. BD Completes Sale of Majority of Discovery Labware Unit
5. Discovery of New "Youth Pill" Revealed At International Scientific Conference
6. Drug Discovery in Rare Diseases
7. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
8. Initiating Rare Disease Drug Discovery Projects
9. Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
10. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
11. Drug Discovery Technologies, BCC Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
(Date:10/7/2017)... Texas , Oct. 6, 2017   Provista, ... with more than $100 billion in purchasing power, today ... news and information. The Newsroom is the ... and industry trends, infographics, expert bios, news releases, slideshows ... having access to a wealth of resources at their ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing an ... to overcome a rare and deadly chromosome abnormality. , After struggling since birth ...
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
Breaking Medicine News(10 mins):